Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: Vendit™ who wrote (1076)	3/4/1998 9:32:00 AM
From: cardiologist to be	Read Replies (1) \| Respond to of 1359

i am not disagreeing with you that ipic has less exposure to redux than ahp or the makers of phen/fen. my point is that when the lawsuits start getting exposure, ipic will take a hit indirectly because most people will not take the time to differentiate the two drugs. when it dips, it may represent another buying opportunity, but one should not buy this stock on margin, unless one is prepared to send more money in when or sell others when the stock falls at various times.

To: Vendit™ who wrote (1076)	3/5/1998 6:37:00 AM
From: jlib	Read Replies (1) \| Respond to of 1359

>"phen/fen is a mixture of 2 separate prescription drugs. Redux is one of those drugs... AHP is the company that is making this cocktail and sending it to market for resale."< Just a bit of clarification on the part of your post above. Redux (dexfenfluramine) was rarely prescribed with phentermine. In fact, AHP explicitly advised against it (according to my pharmacist). The fenfluramine part of the phen/fen combination was Pondimin (in the US) and was not connected with IPIC in any way but was solely an AHP product. Redux was similar to Pondimin in effect and composition. In fact, it could be said that dexfenfluramine was the isolated "active ingredient" in fenfluramine. The phentermine portion was an old line anorectic that had long fallen generic so had numerous sources. The phen/fen combo was not a compounded "cocktail" as such but was simply two separate prescriptions. AHP never actively marketed the unapproved combination to physicians (but neither did they actively discourage it). The phen/fen combo off-label usage derived directly from a four year double blind study published in the early 90's by Dr. Michael Weintraub. Several years elapsed before the efficacy of the combination as revealed in the study was accepted by physicians in general. That hesitation pendulumed to the indiscriminate use witnessed before the withdrawal of Pondimin and Redux. Best, Jimmy Liberato